![](https://www.molecular-medicine-israel.co.il/wp-content/uploads/2018/01/immunotherapy-cancer-300x167.jpg)
Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
Highlights IDO1 and TDO2 catalyze the commitment and rate-limiting step of the KYN metabolic pathway that produces the endogenous AhR agonist KYN. Activation of AhR